脑瘫患儿肌痉挛药物治疗现状(3)
[14] Albavera-Hernandez C， Rodriguez J M， Idrovo A J. Safety of botulinim toxin type A among children with spasticity secondary to cerebral palsy： a systematic review of randomized clinical trials[J]. Clin Rehabil，2009，23(7)：394-407.
[15] Heinen F， Desloovere K， Schroeder A S， et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy[J]. Eur J Paediatr Neurol，2010，14(2)：45-66.
[16] Koman L A， Paterson B， Shilt J S. Cerebral palsy[J]. Lancet，2004，363(9)：1619-1631.
[17] Goldstein E M. Spasticity management： an overview[J]. J Child Neurol，2001，16(3)：16-23.
[18] Tilton A H. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders[J]. J Child Neurol，2003，18(6)：50-66.
[19] Viel E J， Perennou D， Ripart J， et al. Neurolytic blockade of the oburator nerve for intractable apastcity of adductor thigh muscles[J]. Eur J Pain，2002，6(6)：97-104.
[20] Chua K S， Kong K H. Clinical and functional outcome after alcohol neurolysis of the tibial nerve for ankle-foot spasticity[J]. Brain Inj，2001，15(9)：733-739.
[21] Heinen F， Mall V， Berweck S， et al. Critical issues in the use of botulinum toxin A[C]. European Academy of childhood Disability， 12th Annual Meeting， Tubingen， Germany.2000.
[22] Bjornson K， Hays R， Graubert C， et al. Botulinum toxin for spasticity in children with cerebral palsy： a comprehensive evaluation[J]. Pediatrics，2007，120(7)：49-58.
[23] Albavera-Hernandez C， Rodriguez J M， Idrovo A J. Safety of botulinim toxin type A among children with spasticity secondary to cerebral palsy： a systematic review of randomized clinical trials[J]. Clin Rehabil，2009，23(3)：394-407.
[24] Goldstein E M. Spasticity management：an overview[J]. J Child Neurol，2001，16(3)：16-23.
[25] Gilmartin R， Bruce D， Storrs B MB， et al. Intrathecal baclofen for management of spastic cerebral palsy：multicenter trial[J]. J Child Neurol，2000，15(3)：71-73.
[26] Murphy N A， Irwin M C， Hoff C. Intrathecal baclofen therapy in children with cerebral palsy： efficacy and complications[J]. ArchPhys Med Rehabil，2002，83(12)：1721-1725.
[27] Segal L S， Wallach D M， Kanev P M. Potential complications of posterior spine fusion and instrumentation in patients with cerebral palsy treated with intrathecal Baclofen infusion[J]. Spine，2005，30(8)：219-224.
(收稿日期：2012-03-26)(本文编辑：李静), http://www.100md.com(刘华章 肖农)
[15] Heinen F， Desloovere K， Schroeder A S， et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy[J]. Eur J Paediatr Neurol，2010，14(2)：45-66.
[16] Koman L A， Paterson B， Shilt J S. Cerebral palsy[J]. Lancet，2004，363(9)：1619-1631.
[17] Goldstein E M. Spasticity management： an overview[J]. J Child Neurol，2001，16(3)：16-23.
[18] Tilton A H. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders[J]. J Child Neurol，2003，18(6)：50-66.
[19] Viel E J， Perennou D， Ripart J， et al. Neurolytic blockade of the oburator nerve for intractable apastcity of adductor thigh muscles[J]. Eur J Pain，2002，6(6)：97-104.
[20] Chua K S， Kong K H. Clinical and functional outcome after alcohol neurolysis of the tibial nerve for ankle-foot spasticity[J]. Brain Inj，2001，15(9)：733-739.
[21] Heinen F， Mall V， Berweck S， et al. Critical issues in the use of botulinum toxin A[C]. European Academy of childhood Disability， 12th Annual Meeting， Tubingen， Germany.2000.
[22] Bjornson K， Hays R， Graubert C， et al. Botulinum toxin for spasticity in children with cerebral palsy： a comprehensive evaluation[J]. Pediatrics，2007，120(7)：49-58.
[23] Albavera-Hernandez C， Rodriguez J M， Idrovo A J. Safety of botulinim toxin type A among children with spasticity secondary to cerebral palsy： a systematic review of randomized clinical trials[J]. Clin Rehabil，2009，23(3)：394-407.
[24] Goldstein E M. Spasticity management：an overview[J]. J Child Neurol，2001，16(3)：16-23.
[25] Gilmartin R， Bruce D， Storrs B MB， et al. Intrathecal baclofen for management of spastic cerebral palsy：multicenter trial[J]. J Child Neurol，2000，15(3)：71-73.
[26] Murphy N A， Irwin M C， Hoff C. Intrathecal baclofen therapy in children with cerebral palsy： efficacy and complications[J]. ArchPhys Med Rehabil，2002，83(12)：1721-1725.
[27] Segal L S， Wallach D M， Kanev P M. Potential complications of posterior spine fusion and instrumentation in patients with cerebral palsy treated with intrathecal Baclofen infusion[J]. Spine，2005，30(8)：219-224.
(收稿日期：2012-03-26)(本文编辑：李静), http://www.100md.com(刘华章 肖农)